Revision as of 15:21, 7 October 2020 editRogermx (talk | contribs)Extended confirmed users, IP block exemptions, Pending changes reviewers55,203 edits Added wikilinksTag: Visual edit← Previous edit | Revision as of 01:40, 30 May 2023 edit undoEntranced98 (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers173,778 edits Importing Wikidata short description: "Chemical compound"Tag: Shortdesc helperNext edit → | ||
Line 1: | Line 1: | ||
{{Short description|Chemical compound}} | |||
{{Drugbox | {{Drugbox | ||
| Verifiedfields = changed | | Verifiedfields = changed |
Revision as of 01:40, 30 May 2023
Chemical compound Pharmaceutical compoundClinical data | |
---|---|
ATC code | |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.013.449 |
Chemical and physical data | |
Formula | C6H9NO2S |
Molar mass | 159.20 g·mol |
InChI
| |
(what is this?) (verify) |
Citiolone is a drug used in liver therapy.
It is a derivative of the amino acid cysteine. Citilone has also been studied with regards to hypothermia due to it being a hydroxyl free radical scavenger. The drug has been shown to protect hamster cells subjected to temperature conditions of 8-25 °C.
References
- de Barrio M, Tornero P, Prieto A, Sainza T, Zubeldia JM, Herrero T (1997). "Recurrent fixed drug eruption caused by citiolone". Journal of Investigational Allergology & Clinical Immunology. 7 (3): 193–4. PMID 9252880.
- Kruuv, J.; Glofcheski, D.J. (1993). "Further Evidence for Two Modes of Hypothermia Damage". Cryobiology. 30 (3): 313–321. doi:10.1006/cryo.1993.1030. PMID 8370318.
Bile and liver therapy (A05) | |
---|---|
Bile therapy | |
Liver therapy |
This drug article relating to the gastrointestinal system is a stub. You can help Misplaced Pages by expanding it. |